Durable complete response following chemotherapy and trastuzumab for metastatic her2-positive breast cancer

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 2204-2205

  Gullo, G ^a   Zuradelli, M ^b   Sclafani, F ^a   Santoro, A ^b   Crown, J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER REGRESSION; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE; GENE AMPLIFICATION; HER2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 84864955450     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds221     Document Type: Letter

References (5)

1. Beda M, Basso U, Ghiotto C et al. When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients? Tumori 2007; 93: 491-492.
2. Maciá Escalante S, Rodríguez Lescure Á, Pons Sanz V et al. A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy. Clin Transl Oncol 2006; 8: 761-763.
3. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
4. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377-384.
5. Baselga J, Bradbury I, Eidtmann H et al. First results of the NeoALTTO Trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Cancer Res 2011; 70: 24 (abstr S3-3).